BioLineRx Ltd. (NASDAQ:BLRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

A number of other research firms have also recently weighed in on BLRX. HC Wainwright set a $4.00 price target on BioLineRx and gave the company a “buy” rating in a research note on Wednesday, August 9th. Roth Capital set a $3.00 price target on BioLineRx and gave the company a “buy” rating in a research note on Wednesday, August 9th. Maxim Group set a $3.00 price target on BioLineRx and gave the company a “buy” rating in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. began coverage on BioLineRx in a research note on Friday, August 4th. They issued an “outperform” rating and a $3.00 price target on the stock. Finally, ValuEngine cut BioLineRx from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. BioLineRx has a consensus rating of “Buy” and a consensus target price of $2.59.

BioLineRx (NASDAQ:BLRX) opened at 1.04 on Thursday. The stock’s market cap is $99.44 million. The company’s 50 day moving average is $1.07 and its 200 day moving average is $0.97. BioLineRx has a 52 week low of $0.80 and a 52 week high of $1.42.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). Equities analysts predict that BioLineRx will post ($0.24) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/09/zacks-investment-research-upgrades-biolinerx-ltd-blrx-to-hold.html.

A number of hedge funds have recently bought and sold shares of BLRX. Benchmark Capital Advisors increased its position in BioLineRx by 227.3% during the 1st quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. Citadel Advisors LLC increased its position in BioLineRx by 443.4% during the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC bought a new position in BioLineRx during the 1st quarter worth $126,000. KCG Holdings Inc. increased its position in BioLineRx by 715.9% during the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC bought a new position in BioLineRx during the 1st quarter worth $3,018,000. Hedge funds and other institutional investors own 32.27% of the company’s stock.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.